SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/11/21 Agios Pharmaceuticals, Inc. 8-K:8,9 6/11/21 12:236K Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 24K 2: EX-99.1 Miscellaneous Exhibit HTML 29K 3: EX-99.2 Miscellaneous Exhibit HTML 33K 8: R1 Document and Entity Information HTML 46K 10: XML IDEA XML File -- Filing Summary XML 12K 7: XML XBRL Instance -- d843751d8k_htm XML 13K 9: EXCEL IDEA Workbook of Financial Reports XLSX 6K 5: EX-101.LAB XBRL Labels -- agio-20210611_lab XML 53K 6: EX-101.PRE XBRL Presentations -- agio-20210611_pre XML 34K 4: EX-101.SCH XBRL Schema -- agio-20210611 XSD 12K 11: JSON XBRL Instance as JSON Data -- MetaLinks 12± 18K 12: ZIP XBRL Zipped Folder -- 0001193125-21-188265-xbrl Zip 23K
8-K |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM i 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i June 11, 2021
i Agios Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
i Delaware | i 001-36014 | i 26-0662915 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
i 88 Sidney Street, i Cambridge, i MA | i 02139 | |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: i (617) i 649-8600
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
i ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
i ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
i ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
i ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading symbol(s) |
Name of each exchange on which registered | ||
i Common Stock, Par Value $0.001 per share | i AGIO | i Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company i ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On June 11, 2021, Agios Pharmaceuticals, Inc., (the “Company”) issued a press release announcing data from its ongoing phase 2 trial evaluating single agent mitapivat in non-transfusion-dependent α- and ß-thalassemia. Also on June 11, 2021, the Company issued a press release announcing updated data, including patient reported outcome measures, from its phase 3 ACTIVATE and ACTIVATE-T studies of mitapivat in adults with pyruvate kinase deficiency. The data in both press releases will be featured in oral presentations at the European Hematology Association Virtual Congress on June 15, 2021. The full text of these press releases are attached as Exhibits 99.1 and 99.2, respectively, hereto and are incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | Description | |
99.1 | Press release issued June 11, 2021 (mitapivat for thalassemia). | |
99.2 | Press release issued June 11, 2021 (mitapivat for PK deficiency). | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AGIOS PHARMACEUTICALS, INC. | ||||||
Date: June 11, 2021 | By: | |||||
Jacqualyn A. Fouse, Ph.D. Chief Executive Officer |
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
6/15/21 | 8-K | |||
Filed on / For Period end: | 6/11/21 | 4 | ||
List all Filings |